

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Reynolds Memorial Hospital, Inc. 2. 800 Wheeling Avenue Glen Dale, WV 26038-1697		In accordance with letter dated May 25, 2022, 3. License No.: 47-08019-01 is amended in its entirety to read as follows:	4. Expiration Date: February 29, 2024 5. Docket No.: 030-03384 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200	7. Chemical and/or physical form A. Any B. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.

Amendment No. 52

10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-08019-01

Amendment No. 52

Docket or Reference No.:
030-03384

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated September 12, 2013, except therapy use and 1st Floor Stress Lab [ML13274A191]
 - B. Letter dated September 23, 2016 [ML16274A414]
 - C. Email dated March 15, 2017 [ML17082A524]
 - D. Letter dated February 26, 2020 [ML20064G118]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 16, 2022By: _____
Janice Nguyen
Region 1